Session

IBD: Clinical trials I

VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES
VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY
DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

OUTCOMES OF FIRST-LINE BIOLOGICALS IN A MULTICENTER PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS – THE DANISH IBD BIOBANK PROJECT
OUTCOMES OF FIRST-LINE BIOLOGICALS IN A MULTICENTER PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS – THE DANISH IBD BIOBANK PROJECT

OUTCOMES OF FIRST-LINE BIOLOGICALS IN A MULTICENTER PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS – THE DANISH IBD BIOBANK PROJECT
OUTCOMES OF FIRST-LINE BIOLOGICALS IN A MULTICENTER PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS – THE DANISH IBD BIOBANK PROJECT

IBD: Clinical trials I  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

IBD: Clinical trials I  et al.

DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY
DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY

IBD: Clinical trials I  et al.

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

IBD: Clinical trials I  et al.

VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES
VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES

IBD: Clinical trials I  et al.

Item 1 - 10 / 10
1